viewFutura Medical PLC

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED).

The study will recruit approximately 1,000 patients with mild, moderate and severe ED and compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2002 against that of the placebo.

Quick facts: Futura Medical PLC

Price: 31.25 GBX

Market: AIM
Market Cap: £63.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Conviviality puts brakes on dividend as hangover worsens

AIM Journal's Andrew Hore speaks to Proactive Investors about Conviviality (LON:CVL) drowning in worries and looks ahead to the good news to come for erectile dysfunction treatment manufacturer Futura Medical (LON:FUM). Hore also discusses the spectrum of telecommunications activities...

on 17/3/18


Holding(s) in Company

9 hours, 34 minutes ago

Holding(s) in Company

2 days, 5 hours ago

Holding(s) in Company

2 days, 5 hours ago

Holding(s) in Company

1 week, 5 days ago

Holding(s) in Company

3 weeks, 4 days ago

Change of Auditor

on 23/10/19

2 min read